Congress moves to block expanded access to opioid-addiction medications
H.R. 5629 — To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect. · Filed by Erin Houchin (R-IN) · Introduced Sep 30, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill nullifies a February 2024 HHS rule that expanded access to medications for opioid use disorder (primarily buprenorphine and methadone), except for the parts governing accreditation of treatment programs. The rule had loosened prescribing restrictions and expanded who could dispense these medications; voiding it restores prior, more restrictive rules and blocks patients from accessing these medications through newly permitted channels.
Why we flagged it
The bill's operative mechanism is to void a rule that expanded access to medications for opioid use disorder. Despite the clinical framing, the net effect is to restrict patient access to evidence-based treatment by reinstating prior prescribing limitations.
What the text implies
- Voiding the rule may disproportionately harm rural and underserved populations who relied on the expanded prescriber network to access buprenorphine and methadone.
- Reinstating prior restrictions could increase overdose deaths and emergency-department utilization among people with opioid use disorder who lose medication access.
The full analysis lists 4 implications of this text.
Who stands to gain
Opioid treatment program operators (by reducing competition from newly authorized prescribers); Entities with financial interest in restricting medication access